FDA-approved

Bones & muscles

Abaloparatide

Evidence

FDA approved

Class

Parathyroid hormone-related peptide analog

/

Abaloparatide

KEY TAKEAWAY

Abaloparatide is a synthetic analog of parathyroid hormone-related protein approved for postmenopausal women with osteoporosis at high risk of fracture.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A bone-building analog of PTHrP

Approved for

Postmenopausal osteoporosis at high fracture risk

Key fact

Reduced vertebral and non-vertebral fractures in a large trial

Route

Daily injection

Evidence strength

FDA approved

What it is

What it is

Abaloparatide, sold as Tymlos, is a 34-amino-acid peptide modeled on parathyroid hormone-related protein.

How it works

How it works

It activates the PTH1 receptor in a way that favors bone formation over bone breakdown.

Regulatory status

Regulatory status

The FDA approved abaloparatide in 2017 for postmenopausal women with osteoporosis at high fracture risk.

What it is used for

What it is used for

Treatment of postmenopausal osteoporosis in women at high risk of fracture.

Side effects and risks

Side effects and risks

Dizziness, nausea, palpitations and a drop in blood pressure on standing are most common. Raised calcium can also occur.

Citations

Citations

Miller PD et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA. 2016;316:722-733.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo